Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

GeneDx Holdings (WGS) Asset Writedowns and Impairment: 2021-2025

Historic Asset Writedowns and Impairment for GeneDx Holdings (WGS) over the last 1 years, with Sep 2025 value amounting to $29,000.

  • GeneDx Holdings' Asset Writedowns and Impairment was N/A to $29,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $8.4 million, marking a year-over-year change of. This contributed to the annual value of $180,000 for FY2024, which is 98.27% down from last year.
  • Per GeneDx Holdings' latest filing, its Asset Writedowns and Impairment stood at $29,000 for Q3 2025, which was down 32.56% from $43,000 recorded in Q4 2024.
  • GeneDx Holdings' 5-year Asset Writedowns and Impairment high stood at $209.4 million for Q4 2022, and its period low was -$1.3 million during Q3 2021.
  • Its 3-year average for Asset Writedowns and Impairment is $2.1 million, with a median of $43,000 in 2024.
  • In the last 5 years, GeneDx Holdings' Asset Writedowns and Impairment spiked by 20,695.73% in 2022 and then tumbled by 98.11% in 2024.
  • Over the past 5 years, GeneDx Holdings' Asset Writedowns and Impairment (Quarterly) stood at $1.0 million in 2021, then surged by 20,695.73% to $209.4 million in 2022, then spiked by 4,830.23% to $8.3 million in 2023, then plummeted by 98.11% to $43,000 in 2024, then reached $29,000 in 2025.
  • Its Asset Writedowns and Impairment stands at $29,000 for Q3 2025, versus $43,000 for Q4 2024 and $40,000 for Q1 2024.